Patients Requiring Supplemental Oxygen

Offer DEXAMETHASONE, or either HYDROCORTISONE or PREDNISOLONE when dexamethasone cannot be used or is unavailable, to people with COVID-19 who:

Need supplemental oxygen to meet their prescribed oxygen saturation levels or

have a level of hypoxia that needs supplemental oxygen but who are unable to have or tolerate it.

Continue corticosteroids for up to 10 days unless there is a clear indication to stop early, which includes discharge from hospital or a hospital-supervised virtual COVID ward.

TOCILIZUMAB is recommended, within its marking authorisation, as an option for treating COVID-19 in adults who:

Are having systemic corticosteroids AND need supplemental oxygen or mechanical ventilation.

**Please review contraindications carefully**

Remdesivir, Baricitinib – these medications have a conditional recommendation from NICE.

Please review NICE guidelines and consider individual patient characteristics before prescribing.

Casirivimab plus imdevimab is not recommended, within its marketing authorisation, for treating COVID-19.

Sarilumab – NICE have removed the recommendation on sarilumab. The recommendation was for off-label use of sarilumab because it is not licensed for use in COVID-19. This recommendation has been superseded by NICE’s technology appraisal guidance on casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for people with COVID-19, which recommends tocilizumab, an interleukin-6 inhibitor licensed for use in COVID-19.